Literature DB >> 24057344

Plasma urokinase antigen and C-reactive protein predict angina recurrence after coronary angioplasty.

Yelena Parfyonova1, Irina Alekseeva, Olga Plekhanova, Alexander Deev, Elena Titaeva, Anatoly Dobrovolsky, Zufar Gabbasov, Anatoly Lyakishev, Vsevolod Tkachuk.   

Abstract

This study evaluates the predictive value of several biochemical indices of the coagulation-fibrinolysis system, platelet function, and inflammatory state for angina recurrence after successful percutaneous transluminal coronary angioplasty (PTCA). We measured preprocedural and follow-up plasma levels of C-reactive protein (CRP), fibrinogen, and urokinase plasminogen activator antigen (uPA), plasminogen activator inhibitor-1 (PAI-1) activity, tissue plasminogen activator activity, and adenosine diphosphate-induced platelet aggregation in 53 patients with chronic stable angina who underwent successful elective PTCA of single hemodynamically significant lesions in coronary arteries. All patients were followed up for 12 months after PTCA. The Cox proportional hazards model was used to assess the association of variables with angina recurrence rate. At the end of the follow-up, 16 patients had angina recurrence. Among 36 clinical, biochemical, and angiographic variables, the duration of stable angina more than 12 months before PTCA (χ (2) = 5.73; P = 0.02, hazard ratio (HR) 3.7, 95 % confidence interval (CI) 1.26-10.6), high baseline levels of CRP (>7 mg/l) (χ (2) = 8.34; P = 0.004, HR 2.9, 95 % CI 1.4-5.9), uPA antigen baseline (>1 ng/ml) (χ (2) = 17.11; P = 0.0001, HR 11.5, 95 % CI 3.6-36.7) and 48 h after PTCA (χ (2) = 15.73; P = 0.0001, HR 8.8, 95 % CI 3.01-25.96), baseline PAI-1 activity (>18 IU/ml) (χ (2) = 9.37; P = 0.002, HR 7.6, 95 % CI 2.07-27.84) were significant predictors of recurrent angina by univariate analyses. According to stepwise multivariate analyses, only the levels of plasma uPA antigen and serum CRP were shown to be significant independent predictors of angina recurrence (multivariate uPA χ (2) = 8.22, P = 0.004, HR 6.2, 95 % CI 1.78-21.67; CRP χ (2) = 4.09, P = 0.04, HR 1.9, 95 % CI 1.02-3.68). High preprocedural plasma uPA and serum CRP levels are indicative of angina recurrence after successful PTCA, and are valuable for the prognosis of restenosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24057344     DOI: 10.1007/s00380-013-0407-1

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  40 in total

1.  Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA.

Authors:  D Prisco; S Fedi; E Antonucci; M Capanni; L Chiarugi; M Chioccioli; M Falai; C Giglioli; R Abbate; G F Gensini
Journal:  Thromb Res       Date:  2001-11-01       Impact factor: 3.944

2.  CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases: a background paper.

Authors:  Luigi M Biasucci
Journal:  Circulation       Date:  2004-12-21       Impact factor: 29.690

3.  Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  F Haverkate; S G Thompson; S D Pyke; J R Gallimore; M B Pepys
Journal:  Lancet       Date:  1997-02-15       Impact factor: 79.321

4.  Applying the National Institute for Clinical Excellence criteria to patients treated with the Genous™ Bio-engineered R stent™: a sub-study of the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) worldwide registry.

Authors:  Margo Klomp; Peter Damman; Marcel A M Beijk; Sigmund Silber; Manfred Grisold; Expedito E Ribeiro; Harry Suryapranata; Jaroslaw Wòjcik; Kui Hian Sim; Jan G P Tijssen; Robbert J de Winter
Journal:  Heart Vessels       Date:  2011-07-02       Impact factor: 2.037

Review 5.  Role of platelets in restenosis after percutaneous coronary revascularization.

Authors:  H Le Breton; E F Plow; E J Topol
Journal:  J Am Coll Cardiol       Date:  1996-12       Impact factor: 24.094

Review 6.  The molecular mechanisms of vascular restenosis: Which genes are crucial?

Authors:  Jemma Bhoday; Sampath de Silva; Qingbo Xu
Journal:  Curr Vasc Pharmacol       Date:  2006-07       Impact factor: 2.719

7.  Contrasting effects of urokinase and tissue-type plasminogen activators on neointima formation and vessel remodelling after arterial injury.

Authors:  Yelena Parfyonova; Olga Plekhanova; Marina Solomatina; Vladimir Naumov; Alex Bobik; Bradford Berk; Vsevolod Tkachuk
Journal:  J Vasc Res       Date:  2004-06-07       Impact factor: 1.934

8.  Differences in absolute risk of cardiovascular events using risk-refinement tests: a systematic analysis of four cardiovascular risk equations.

Authors:  Emil M deGoma; Richard L Dunbar; Douglas Jacoby; Benjamin French
Journal:  Atherosclerosis       Date:  2012-12-31       Impact factor: 5.162

9.  Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain.

Authors:  J Heinrich; H Schulte; R Schönfeld; E Köhler; G Assmann
Journal:  Thromb Haemost       Date:  1995-03       Impact factor: 5.249

10.  Plasminogen activator inhibitor-1 predicts coronary in-stent restenosis of drug-eluting stents.

Authors:  K M Katsaros; W S Speidl; S P Kastl; G Zorn; K Huber; G Maurer; D Glogar; J Wojta; G Christ
Journal:  J Thromb Haemost       Date:  2007-12-25       Impact factor: 5.824

View more
  1 in total

1.  Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors?

Authors:  Ayumi Nakamura; Shin-Ichiro Miura; Yuhei Shiga; Kenji Norimatsu; Yuiko Miyase; Yasunori Suematsu; Ryoko Mitsutake; Keijiro Saku
Journal:  Heart Vessels       Date:  2014-07-22       Impact factor: 2.037

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.